UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16

OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2021

 

Commission file number: 001-38775

 

ITAMAR MEDICAL LTD.

(Name of registrant)

 

9 Halamish Street, Caesarea 3088900, Israel

(Address of principal executive office)

_____________________

 

        Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨

 

        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

____________________

 

 

 

 

 

EXPLANATORY NOTE

 

On August 12, 2021, Itamar Medical Ltd. announced the appointment of Ms. Marga Ortigas-Wedekind to its Board of Directors and issued a press release entitled "Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors", which is attached to this Form 6-K as Exhibit 99.1.

 

This Form 6-K, excluding Exhibit 99.1, is incorporated by reference into the registration statements on Form F-3 (File No. 333-252364 and 333-250155) and on Form S-8 (File No. 333-236883 and 333-230799) of the Company, filed with the SEC, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

Exhibits

 

Exhibit
Number
  Description
99.1   Press Release, August 12, 2021: Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

 

 

 

 

SIGNATURES

  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ITAMAR MEDICAL LTD.
     
     
  By: /s/ Shy Basson
 

Shy Basson

Chief Financial Officer 

 

Date: August 12, 2021

 

 

 

Exhibit 99.1

 

 

 

Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

 

CAESAREA, Israel, August 12, 2021 -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors.

 

Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy guidance and defining the digital health strategy. Prior, Ortigas-Wedekind served as EVP, Marketing and Payer Relations for iRhythm Technologies (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care. Previously she was EVP, Global Marketing and Product Development at Omnicell Inc (NASDAQ:OMCL). Earlier in her career, she was SVP, Marketing, Development, and Clinical Affairs at Xoft, Inc. (now iCAD) and VP, Sales and Marketing at Pro-Duct Health, Inc. (now Hologic).

 

“We are pleased to welcome Marga to Itamar’s board,” said Dr. Giora Yaron, Chairman of Itamar’s Board of Directors. “Her background and experience in the healthcare and digital health sectors perfectly align with our long-term goals..”

 

Mrs. Ortigas-Wedekind earned a master’s degree in International Business and Marketing from the Stanford Graduate School of Business and a bachelor’s degree in Political Economy from Wellesley College. She currently serves as an Advisory Committee Member at Launchpad Digital Health and a Member of HealthTech Capital.

 

About Itamar Medical Ltd.

Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs. The Company’s key product, WatchPAT, is commercially available within major markets including the US, Japan, and Europe. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com

 

Itamar Medical Investor Relations Contact (U.S.)

Leigh Salvo

Gilmartin Group

Phone: +1-510-693-5238

investors@itamar-medical.com